All Stories

  1. Enhanced behavioral responses to ghrelin administration are unaffected by ghrelin deficiency in a DHT-induced PCOS mouse model
  2. Genomic analyses implicate hormonal and metabolic dysregulation in polycystic ovary syndrome
  3. Later age of natural menopause among women with the pathogenic CHEK2 c.1100delC variant: a validation study
  4. The impact of immune checkpoint inhibitors on gonadal function in patients with solid tumors
  5. AMH as a marker for resumption of ovarian function after chemotherapy: an IPD meta-analysis and systematic review
  6. Functional characterisation of obesity-associated MRAP2 variants on MC4R and GHSR signalling
  7. 11-Oxygenated Androgens Inhibit Brown Adipose Tissue Differentiation
  8. Sex differences in leptin levels in children and adolescents with normal weight and overweight/obesity across pubertal stages: a systematic review and meta-analysis
  9. SUL-138 mitigates accelerated endothelial aging and protects the kidney
  10. Early prediction of menopausal status after chemotherapy in women with early breast cancer in order to optimize adjuvant endocrine therapy
  11. Sex steroids and women’s physical performance in midlife: Findings from the Menarche-to-PreMenopause Study
  12. Role of mitochondrial function in the oxidative stress profile of children with Prader-Willi syndrome
  13. POLYCYSTIC OVARY SYNDROME: ORIGINS AND IMPLICATIONS: Genetics of polycystic ovary syndrome (PCOS)
  14. Navigating the Strengths and Constraints of Mouse Models in Obesity Research
  15. The Role of Anti-Müllerian Hormone in Ovarian Function
  16. OR0303 Syndecans Enhance Ghrelin-Induced GHSR1a Signaling
  17. Comparison of 3 Different AMH Assays With AMH Levels and Follicle Count in Women With Polycystic Ovary Syndrome
  18. Comparison of three different AMH assays with AMH levels and follicle count in women with polycystic ovary syndrome
  19. Association between an AMH promoter polymorphism and serum AMH levels in PCOS patients
  20. Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids
  21. The importance of metabolic dysfunction in polycystic ovary syndrome
  22. Serum AMH Levels: An Early Reproductive Marker for Bone Loss?
  23. Current insights into the genetics of polycystic ovary syndrome
  24. Association between an AMH promoter polymorphism and serum AMH levels in PCOS patients
  25. AMH in PCOS: Controlling the ovary, placenta, or brain?
  26. SUN-008 Loss of Antimullerian Hormone Immunoreactivity Due to a Homozygous AMH Gene Mutation Rs10417628 in a Woman with Classical Polycystic Ovary Syndrome
  27. Fetal antecedents of PCOS: is there a role of AMH?
  28. Homozygous antimullerian hormone (AMH) gene mutation rs10417628 in a polycystic ovary syndrome (PCOS) woman with exaggerated hyperandrogenism
  29. MON-208 Association Study of AMH Promoter Polymorphisms and Serum AMH Levels in PCOS Patients
  30. Multiple effects of cold exposure on livers of male mice
  31. Sex differences in glucocorticoid-induced metabolic disturbances in mice
  32. Associations Between Systemic and Local Corticosteroid Use With Metabolic Syndrome and Body Mass Index
  33. The Acylated/Unacylated Ghrelin Ratio Is Similar in Patients With Acromegaly During Different Treatment Regimens
  34. The Steroid Metabolome in the Isolated Ovarian Follicle and Its Response to Androgen Exposure and Antagonism
  35. Menopause: Genome stability as new paradigm
  36. Metabolic dysfunction in a rodent model of PCOS
  37. Shaping up the function of anti-Müllerian hormone in ovaries of mono-ovulatory species
  38. Evidence that neuropeptide FF receptor type 1 is not the physiological unacylated ghrelin receptor
  39. Mouse models to study polycystic ovary syndrome: A possible link between metabolism and ovarian function?
  40. Role of anti-Müllerian hormone and bone morphogenetic proteins in the regulation of FSH sensitivity
  41. Limitations and pitfalls of antimüllerian hormone measurements
  42. Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency
  43. A Novel <b><i>AMH</i></b> Missense Mutation in a Patient with Persistent Müllerian Duct Syndrome
  44. Anti-Müllerian hormone (AMH): Regulator and marker of ovarian function
  45. Variants in the ACVR1 gene are associated with AMH levels in women with polycystic ovary syndrome
  46. A Functional Anti-Müllerian Hormone Gene Polymorphism Is Associated with Follicle Number and Androgen Levels in Polycystic Ovary Syndrome Patients
  47. Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality?
  48. AMH TYPE II RECEPTOR DEFICIENT MICE DISPLAY A MORE SEVERE OVARIAN PHENOTYPE THAN AMH DEFICIENT MICE
  49. Anti-Müllerian hormone and folliculogenesis
  50. AMH signaling: from receptor to target gene
  51. Anti-Müllerian hormone and its role in ovarian function
  52. Regulation of ovarian function: the role of anti-Mullerian hormone
  53. Downstream factors in transforming growth factor-β family signaling
  54. Effect of Prenatal Exposure to Diethylstilbestrol on Müllerian Duct Development in Fetal Male Mice1